1. Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm [Suppl] 28: 21–31.
2. Cocchiara G, Battaglia R, Pevarello P, Strolin Benedetti M (1991) Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur J Drug Metab Pharmacokinet 16: 231–239.
3. Dollery CT, Brown MJ, Davies DS, Strolin Benedetti M (1984) Pressor amines and monoamine oxidase inhibitors. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London, pp 429–441.
4. Dostert P (1984) Myth and reality of the classical MAO inhibitors. Reasons for seeking a new generation. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London, pp 9–24.
5. Dostert P, Strolin Benedetti M, Sontag N (1981) Some biochemical aspects of the potential benefit of associating MD 780515 with tricyclic antidepressants. J Pharm Pharmacol 33: 639–643.